VERTEX PHARMACEUTICALS INC / MA Effective Tax Rate
VERTEX PHARMACEUTICALS INC / MA (VRTX) reported Effective Tax Rate of 21.00% for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateContinuingOperations · last filed 2026-08-04
- VERTEX PHARMACEUTICALS INC / MA effective income tax rate reconciliation, percent for the quarter ending 2026-06-30 was 21.00%, a 7.69% increase year-over-year.
- VERTEX PHARMACEUTICALS INC / MA effective income tax rate reconciliation, percent for the quarter ending 2026-03-31 was 17.70%, a 53.91% increase year-over-year.
- VERTEX PHARMACEUTICALS INC / MA effective income tax rate reconciliation, percent for the quarter ending 2025-09-30 was 16.60%, a 13.70% increase year-over-year.
- VERTEX PHARMACEUTICALS INC / MA effective income tax rate reconciliation, percent for the quarter ending 2025-06-30 was 19.50%.
- VERTEX PHARMACEUTICALS INC / MA effective income tax rate reconciliation, percent for fiscal 2025 was 14.90%, a 95.28% decline from fiscal 2024.
- VERTEX PHARMACEUTICALS INC / MA effective income tax rate reconciliation, percent for fiscal 2024 was 315.50%, a 1713.22% increase from fiscal 2023.
- VERTEX PHARMACEUTICALS INC / MA effective income tax rate reconciliation, percent for fiscal 2023 was 17.40%, a 19.07% decline from fiscal 2022.
- VERTEX PHARMACEUTICALS INC / MA effective income tax rate reconciliation, percent for fiscal 2022 was 21.50%, a 51.41% increase from fiscal 2021.
| Period end | Effective Income Tax Rate Reconciliation, Percent 3 month | Effective Income Tax Rate Reconciliation, Percent 3 month as first filed | Effective Income Tax Rate Reconciliation, Percent 6 month | Effective Income Tax Rate Reconciliation, Percent 6 month as first filed | Effective Income Tax Rate Reconciliation, Percent 9 month | Effective Income Tax Rate Reconciliation, Percent 9 month as first filed | Effective Income Tax Rate Reconciliation, Percent 12 month | Effective Income Tax Rate Reconciliation, Percent 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | 21.00% 10-Q · filed 2026-08-04 | 19.40% 10-Q · filed 2026-08-04 | ||||||
| 2026-03-31 | 17.70% 10-Q · filed 2026-05-05 | |||||||
| 2025-12-31 | 14.90% 10-K · filed 2026-02-13 | |||||||
| 2025-09-30 | 16.60% 10-Q · filed 2025-11-04 | 16.60% 10-Q · filed 2025-11-04 | ||||||
| 2025-06-30 | 19.50% 10-Q · filed 2026-08-04 | 16.60% 10-Q · filed 2026-08-04 | ||||||
| 2025-03-31 | 11.50% 10-Q · filed 2026-05-05 | |||||||
| 2024-12-31 | 315.50% 10-K · filed 2026-02-13 | |||||||
| 2024-09-30 | 14.60% 10-Q · filed 2025-11-04 | -63.10% 10-Q · filed 2025-11-04 | ||||||
| 2024-06-30 | -6.00% 10-Q · filed 2025-08-05 | -18.10% 10-Q · filed 2025-08-05 | ||||||
| 2024-03-31 | 14.00% 10-Q · filed 2025-05-06 | |||||||
| 2023-12-31 | 17.40% 10-K · filed 2026-02-13 | |||||||
| 2023-09-30 | 12.20% 10-Q · filed 2024-11-05 | 18.00% 10-Q · filed 2024-11-05 | ||||||
| 2023-06-30 | 21.20% 10-Q · filed 2024-08-02 | 21.30% 10-Q · filed 2024-08-02 | ||||||
| 2023-03-31 | 21.50% 10-Q · filed 2024-05-07 | |||||||
| 2022-12-31 | 21.50% 10-K · filed 2025-02-13 | |||||||
| 2022-09-30 | 20.90% 10-Q · filed 2023-11-07 | 21.00% 10-Q · filed 2022-10-28 | 20.70% 10-Q · filed 2023-11-07 | 21.00% 10-Q · filed 2022-10-28 | ||||
| 2022-06-30 | 20.90% 10-Q · filed 2023-08-02 | 21.00% 10-Q · filed 2022-08-05 | 20.50% 10-Q · filed 2023-08-02 | 21.00% 10-Q · filed 2022-08-05 | ||||
| 2022-03-31 | 20.20% 10-Q · filed 2023-05-02 | 20.00% 10-Q · filed 2022-05-06 | ||||||
| 2021-12-31 | 14.20% 10-K · filed 2024-02-15 | |||||||
| 2021-09-30 | 21.00% 10-Q · filed 2022-10-28 | 15.00% 10-Q · filed 2022-10-28 | ||||||
| 2021-06-30 | 251.00% 10-Q · filed 2022-08-05 | 7.00% 10-Q · filed 2022-08-05 | ||||||
| 2021-03-31 | 20.00% 10-Q · filed 2022-05-06 | |||||||
| 2020-12-31 | 13.00% 10-K · filed 2023-02-10 | |||||||
| 2020-09-30 | 11.00% 10-Q · filed 2021-11-03 | 5.00% 10-Q · filed 2021-11-03 | ||||||
| 2020-06-30 | -2.00% 10-Q · filed 2021-07-30 | 3.00% 10-Q · filed 2021-07-30 | ||||||
| 2020-03-31 | 8.00% 10-Q · filed 2021-04-30 | |||||||
| 2019-12-31 | 15.60% 10-K · filed 2022-02-09 | 16.00% 10-K · filed 2021-02-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |